Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Retained Earnings (2016 - 2025)

Vistagen Therapeutics' Retained Earnings history spans 12 years, with the latest figure at -$461.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 4191400.0% year-over-year to -$461.0 million; the TTM value through Dec 2025 reached -$461.0 million, down 4191400.0%, while the annual FY2025 figure was -$407.6 million, 14.43% down from the prior year.
  • Retained Earnings for Q4 2025 was -$461.0 million at Vistagen Therapeutics, down from $14000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $14000.0 in Q3 2025 and bottomed at -$461.0 million in Q4 2025.
  • The 4-year median for Retained Earnings is -$333.8 million (2023), against an average of -$265.8 million.
  • The largest YoY upside for Retained Earnings was 100.0% in 2025 against a maximum downside of 21136450.0% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$250.9 million in 2021, then tumbled by 38.17% to -$346.7 million in 2023, then skyrocketed by 100.0% to $11000.0 in 2024, then plummeted by 4191400.0% to -$461.0 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Retained Earnings are -$461.0 million (Q4 2025), $14000.0 (Q3 2025), and -$422.7 million (Q2 2025).